Microfluidics Market Size to Soar USD 103.06 Billion by 2033

Microfluidics Market Size, Shares and Trends Report

The global microfluidics market size was estimated at US$ 31.80 billion in 2023 and is projected to grow to US$ 103.06 billion by 2033, rising at a compound annual growth rate (CAGR) of 12.50% from 2024 to 2033. The market is anticipated to develop as microfluidics devices become more widely used in diagnostic and research settings.

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

• By region, North America dominated the microfluidics market in 2023.
• By region, Asia Pacific is expected to grow at the fastest rate during the forecast period.
• By application, the medical/healthcare segment held the largest share of the market in 2023.
• By material, the PDMS segment dominated the market with the largest share in 2023.
• By technology, the lab-on-a-chip segment held the dominant share of the market in 2023.

Industry at a Glance

A system that manipulates a limited number of fluids through tiny channels that range in size from ten to hundreds of micrometers is known as microfluidics. The study of fluid behavior through microchannels and the technology for creating microminiaturized devices with chambers and tunnels that allow fluids to flow or be contained are combined to form the microfluidics market. Molecular biology, microelectronics, and analysis are all interdisciplinary fields that are part of the microfluidics business. It may be usefully incorporated into the design of low-volume fluid processing systems to accomplish high-throughput screening, multiplexing and automation. The increasing use of microfluidics technology and devices in point-of-care diagnostics, the development of diagnostic devices through technology, and the global rise in the prevalence of chronic illnesses are the main drivers of the microfluidics market.

Key Players and Components in the Microfluidics Market Ecosystem

The microfluidics market ecosystem is shaped by several core components and leading companies that drive innovation and growth. At its heart, microfluidics involves precise control of fluid flows in micro-scale channels, essential for applications in diagnostics, drug delivery, and biological research.

Key components of this ecosystem include microfluidic devices, which integrate microchannels, sensors, and valves to manipulate small volumes of fluids. These devices are critical in lab-on-a-chip systems, enabling rapid and efficient analysis.

Leading companies in the microfluidics market contribute significantly by developing and refining these technologies. For instance, companies like Illumina and Fluidigm focus on advanced microfluidic devices for genomics and proteomics. PerkinElmer and Agilent Technologies provide sophisticated microfluidic systems for analytical and clinical applications. Dolomite Microfluidics and Syrris are known for their innovative microfluidic components and solutions, enhancing lab automation and chemical synthesis. LabSmith and Micronit Microtechnologies offer customizable microfluidic platforms for a wide range of research and industrial needs.

Together, these components and companies create a dynamic and evolving microfluidics ecosystem, pushing the boundaries of scientific discovery and practical applications.

Top Companies in the Microfluidics Market

• Abbott
• RedShiftBio
• Takara Bio Inc.
• Agilent Technologies, Inc.
• Standard BioTools
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific
• Danaher Corporation
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.

Recent Development by Takara Bio Inc. in the Microfluidics Market

Recent Development by RedShiftBio in the Microfluidics Market

Point-of-Care (POC) Demand is Driving the Microfluidics Market

The microfluidics market is expanding due in large part to the rising need for point-of-care (POC) diagnostics. With POC testing, there is no need for laborious laboratory processing because quick and easy diagnostic findings may be obtained right at the patient's side. In situations like emergency rooms, clinics, and remote or resource-constrained settings, where prompt diagnostic and treatment decisions are vital, this skill is especially important. Because they automate and downsize intricate laboratory procedures onto a tiny chip or cartridge, microfluidic devices are essential to POC testing.

For instance,

• In June 2023, the first point-of-care testing system for the quick diagnosis of antibiotic susceptibility was introduced by Sysmex Corporation in Europe. The urine samples from patients suspected of having urinary tract infections (UTIs) are used by the System to determine if bacteria are present or absent and to evaluate the efficacy of antimicrobials1. When opposed to the many days needed for standard antimicrobial susceptibility testing (AST), the System's use of a special and patented microfluidic technology allows it to produce data in as little as 30 minutes from the start of measurement.

Complex Process Restraints the Microfluidics Market

To guarantee the effectiveness and safety of the equipment, manufacturers of medical devices must abide by strict regulatory standards. In recent years, there has been a significant increase in the time and complexity of the medical device approval process. For some integrated microfluidic medical devices, obtaining regulatory clearance may take some time, and if the authority rejects the device, there is a chance that investment may be wasted. Businesses confront a significant obstacle when introducing novel and cutting-edge items to the market. The expansion of the microfluidics market is being hampered by these issues.

Wearable Devices Hold Great Potential for the Microfluidics Market

With a lot of promise in the healthcare industry, microfluidics has become a very interesting and promising technology. There is a plethora of opportunities in many industries because of its exceptional capacity to manage tiny sample numbers, execute fast replies, and get high sensitivity and throughput data. Personalized healthcare and medical diagnosis could benefit greatly from wearable microfluidics, a ground-breaking invention that was made possible by the combination of microfluidics and cutting-edge technologies such as biosensors, soft materials, artificial intelligence (AI), and microelectronics and combined with IoT, AI, IoMT, and IoP. In order to improve healthcare results, more sophisticated technologies will likely be used in the field, leading to more innovative approaches, better integration techniques, and a wider variety of microfluidic wearable devices.

Report Highlights

Application Insights

The medical/healthcare segment held the largest share of the microfluidics market in 2023. Microfluidic systems provide a range of biomedical techniques and technologies to improve human well-being and convenience. These systems' developments pave the way for next-generation microfluidics, which incorporate automation, manipulation, and intelligent readout systems. The necessity for point-of-care (POC) testing and quick technical advancements in molecular diagnostics has increased due to an aging population, an increase in chronic illness cases, and the health demands of developing nations. These are the main drivers propelling the rise of the market for lab-on-a-chip components in microfluidics.

For instance,

• In April 2024, a novel platform that facilitates and lowers the cost of studying single cells was created by the Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP). The platform, called OptiDrop, may be used in medicine, agriculture, animal health, and diagnostics. The innovative microfluidic chip-based platform dispenses with the costly open space and large optical components that are commonly used in flow cytometry- and microscopy-based procedures and enables optical detection of biological samples.

Material Insights

The PDMS segment dominated the microfluidics market with the largest share in 2023. One substance that commonly comes up in academic discussions about microfluidics is polydimethylsiloxane (PDMS). Its widespread application in microfluidic experiments has led to a notable increase in its popularity and reputation among scholars and researchers. PDMS is a polymer that is frequently employed in academic microfluidic labs because of its beneficial qualities, which include transparency, biocompatibility, and comparatively easy replication.

Technology Insights

The lab-on-a-chip segment held the dominant share of the microfluidics market in 2023. Numerous applications, such as DNA analysis, human diagnostics, and, to a lesser extent, chemical synthesis, are the focus of lab-on-a-chip research. Because the downsizing of biochemical processes lowers costs, parallelizes operations, and improves diagnostic speed, sensitivity, and accuracy, lab-on-a-chip becomes a viable diagnostic tool. In addition to showcasing integration and parallelization capabilities, lab-on-a-chip outperforms traditional technologies in terms of performance. Genetic sequencing has a whole new range of possibilities thanks to lab-on-a-chip technology. Given the latest findings and solutions that have entered the microfluidics industry, lab-on-a-chip is poised to significantly transform the practice of diagnostics. The need for lab-on-a-chip testing in clinical diagnosis is growing, and a number of devices have been brought to market for important uses, such as heart attack diagnoses, HIV detection, and glucose monitoring.

Regional Insights

North America dominated the microfluidics market in 2023. Additionally, it is projected that the region will increase significantly during the predicted period. The use of contemporary miniaturized technologies, the existence of developed economies with their established healthcare infrastructure, and ongoing R&D endeavors by both public and private entities are propelling market expansion in this area. The supremacy of the region was mostly attributed to the U.S. The nation is home to several brand-new microfluidics businesses in addition to numerous well-established ones. In the U.S., point-of-care plays a significant role in microfluidics market dynamics. A number of parties, such as the government, businesses, and influential figures, are implementing incentives to include point-of-care in the management of various illnesses.

For instance,

• In June 2024, Cepheid was authorized by the U.S. Food and Drug Administration to commercialize the Xpert HCV test and GeneXpert Xpress System. These are the first tests for the hepatitis C virus (HCV) that may be used to diagnose patients at risk for the disease in adequately accredited point-of-care settings. The test can be conducted in locations covered by a CLIA (Clinical Laboratory Improvement Amendments) Certificate of Waiver, including some treatment centers for substance use disorders, jails, programs for syringe services, physician offices, emergency rooms, and urgent care centers. The test uses a blood sample from the fingertip to identify HCV RNA and provides findings in approximately an hour, eliminating the need to send a sample to a central lab for testing.

Asia Pacific is expected to grow at the fastest rate during the forecast period. Some of the main factors propelling the growth of the microfluidics market include the increasing demand from the biomedical and pharmaceutical sectors, PoCT, the rising prevalence of chronic illnesses, and increased R&D spending, especially in China. In the area, several methods are being developed and evaluated for 30 printing microfluidic devices with fluid management and operational components.

In order to modernize the nation's industrial sector completely and establish China as a significant actor that is independent of other nations, the Chinese government has developed a strategic plan. The "Made in China 2025" initiative has a special emphasis on medications and medical equipment. By 2025, businesses in these areas will have access to nearly limitless capital, enabling them to compete with overseas businesses and reclaim a sizable portion of the market. Microfluidic technology, a vital tool for life sciences applications and diagnostics, will undoubtedly profit from this significant investment. Large multinational corporations like Roche and Abbott now dominate the Chinese diagnostics industry, but new Chinese enterprises are starting to compete with them.

The microfluidics industry is expanding due in part to the efforts of nations like India. The Indian Microfluidics Association (IMA), for example, was founded on January 1st, 2024, and marks a significant advancement in scientific cooperation and innovation in India. This innovative project, supported by six committed visionaries from business, research, and academia, represents a turning point in the understanding and investigation of microfluidics. Fueled by an uncompromising dedication to pushing the frontiers of this multidisciplinary discipline, the IMA cultivates a vibrant community of experts, scientists, and engineers working at the intersection of biology, nanotechnology, and fluid dynamics. The IMA sees itself as a key platform for the dynamic interchange of ideas that will define the future of microfluidics science, not only in India but worldwide. It positions itself as a catalyst for cutting-edge research and development.

Recent Developments in the Microfluidics Market

• In May 2024, scientists at the National Institute of Standards and Technology (NIST) created bioelectronic instruments that can analyze cell activities in real-time. Researchers are including these elements in their adaptation of the heart-on-a-chip (HoC) system. With a heavy reliance on animal testing, traditional cardiovascular medication research has several shortcomings that this approach aims to solve. The Human Cardiac Model (HoC) has the potential to expedite drug development and save costs by substituting animal research with a more realistic model of the human body, which may capture important characteristics of the human cardiovascular system in a lab setting.
• In April 2024, Boston Micro Fabrication (BMF) is pleased to announce the establishment of BMF Biotechnology Inc. to further facilitate the application of extremely accurate microfluidic solutions in advanced drug development, pharmaceutical, and cosmetic research. BMF Biotechnology Inc., a California company with its headquarters in San Diego, is committed to creating and marketing cutting-edge BioChips—organs-on-a-chip platforms—by growing large-scale tissues in vitro and accelerating the development of novel drugs and cosmetics.
• In March 2023, in droplet microfluidic applications, a novel technique utilizing on-chip fiber optics allows for multiplexed fluorescence and scatter detection with previously unheard-of single-cell precision, according to a paper published in the journal Microsystems & Nanoengineering.
• In May 2023, researchers at the University of Birmingham established a route towards 3D-bioprinted microfluidic tissues, organs, and arteries. By employing 3D bioprinting, research from the University of Birmingham may be able to shorten the lengthy waiting lists for organ transplants. The group claims that its research will hasten the implementation of microfluidic-based tissue in collaboration with collaborators at the University of Huddersfield and the Polytechnic University of Milan.

Segments Covered in the Report

By Application

• Medical/Healthcare
  
  • PCR & RT-PCR
  • Gel Electrophoresis
  • Microarrays
  • ELISA
  • Others
• Non-medical

By Material

• Silicon
• Glass
• Polymer
• PDMS
• Others

By Technology

• Lab-on-a-chip
  
  • Medical
  • Non-Medical
• Organs-on-chips
  
  • Medical
  • Non-Medical
• Continuous Flow Microfluidics
  
  • Medical
  • Non-Medical
• Optofluidics And Microfluidics
  
  • Medical
  • Non-Medical
• Acoustofluidics And Microfluidics
  
  • Medical
  • Non-Medical
• Electrophoresis And Microfluidics
  
  • Medical
  • Non-Medical

By Region

• North America 
  
  • U.S.
  • Canada
• Europe 
  
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific 
  
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Latin America 
  
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA) 
  
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Relevant Report

Harnessing Microbial Fermentation: A Path to Sustainable and Valuable Products

Microbial fermentation technology uses microorganisms and enzymes to produce valuable products for industries like food, chemicals, pharmaceuticals, energy, and materials. This ancient method, originally used for brewing beer, now creates things like hormones, enzymes, antibiotics, and vitamins. It's used in making beverages (like wine and beer), solvents (like acetone and alcohol), and various other products.

The market for microbial fermentation technology is growing quickly. It helps produce important compounds for many industries and supports the shift towards more sustainable, bio-based solutions.

• The global microbial fermentation technology market was valued at approximately $34.11 billion in 2023. It is expected to reach $60.17 billion by 2033, with a compound annual growth rate (CAGR) of 5.84% from 2024 to 2033. This growth is driven by the rising demand for biologics.